Skip to main content
GELS
NASDAQ Life Sciences

Gelteq Ltd Receives Nasdaq Delisting Notice for Sub-$1.00 Share Price

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.71
Mkt Cap
$7.607M
52W Low
$0.64
52W High
$4.11
Market data snapshot near publication time

summarizeSummary

Gelteq Ltd has been notified by Nasdaq that it is not in compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance and avoid potential delisting.


check_boxKey Events

  • Nasdaq Minimum Bid Price Deficiency

    Gelteq Ltd received a letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).

  • 180-Day Compliance Period Initiated

    The company has a compliance period of 180 calendar days, until September 14, 2026, to regain compliance by having its ordinary shares close at or above $1.00 for at least ten consecutive business days.

  • Potential for Additional Grace Period

    If compliance is not met by the deadline, the company may be eligible for an additional 180-day grace period, provided it meets other listing standards and intends to cure the deficiency, potentially through a reverse stock split.

  • Shares Continue to Trade

    The Nasdaq notification does not result in immediate delisting, and the company's shares will continue to trade uninterrupted under the symbol "GELS".


auto_awesomeAnalysis

This Nasdaq notification signals a critical risk for Gelteq Ltd, as maintaining a listing on a major exchange is vital for investor visibility and liquidity, particularly for a micro-cap company. Failure to regain compliance by September 14, 2026, could lead to delisting, potentially forcing the company to consider a reverse stock split or move to an over-the-counter market. Such a move often results in reduced trading volume and investor interest, further complicating capital-raising efforts. Investors should closely monitor the company's stock price performance and any strategic actions announced to address this deficiency.

At the time of this filing, GELS was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6M. The 52-week trading range was $0.64 to $4.11. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed GELS - Latest Insights

GELS
Mar 24, 2026, 8:15 AM EDT
Filing Type: 6-K
Importance Score:
9